Figure 1: TSC22D4 controls intra-hepatic insulin signalling.
From: Control of diabetic hyperglycaemia and insulin resistance through TSC22D4
(a) Western blot analysis from representative negative control (NC shRNA) or TSC22D4 (TSC shRNA) shRNA adenovirus-treated primary mouse hepatocytes using indicated antibodies. Right: quantification of the phospho-immunoblots normalized to corresponding total protein levels (y axis is in arbitrary units). Statistical analysis: Student’s t-test. *P≤0.05; **P≤0.01; ***P≤0.001. Error bars indicate standard error of the mean (s.e.m.). (b) Western blot analysis of liver extracts from representative control (shNC) or TSC22D4 (shTSC) shRNA adenovirus-injected C57Bl/6 mice 7 days after injection using indicated antibodies. Right: quantification of the phospho-immunoblots normalized to corresponding total protein levels (y axis is in arbitrary units). Animals were injected i.p. with either PBS or insulin 20 min before sacrifice. (c) Western blot analysis of liver extracts from 16 h fasted or 30 min refed control (shNC) or TSC22D4 (shTSC) shRNA adenovirus-injected C57Bl/6 mice 7 days after injection using indicated antibodies. Bottom: Quantification of the phospho-immunoblots normalized to corresponding total protein levels (y axis is in arbitrary units). Statistical analysis: two way ANOVA with multiple comparisons test; **P≤0.01; ****P≤0.0001. Error bars in b,c, indicate standard deviation (s.d). (d) Western blot analysis of liver extracts from representative empty control (ctrl cDNA) or Flag-TSC22D4 cDNA adenovirus-injected C57Bl/6 mice 7 days after injection using indicated antibodies. Following 18 h of fasting, mice were refed for 6 h before sacrifice.
